ATE424845T1 - Thermoreversible immunadjuvansemulsion - Google Patents

Thermoreversible immunadjuvansemulsion

Info

Publication number
ATE424845T1
ATE424845T1 AT06778810T AT06778810T ATE424845T1 AT E424845 T1 ATE424845 T1 AT E424845T1 AT 06778810 T AT06778810 T AT 06778810T AT 06778810 T AT06778810 T AT 06778810T AT E424845 T1 ATE424845 T1 AT E424845T1
Authority
AT
Austria
Prior art keywords
immunadjuvant
thermoreversible
emulsion
thermoreversible immunadjuvant
immunadjuvant emulsion
Prior art date
Application number
AT06778810T
Other languages
English (en)
Inventor
Marie-Francoise Klucker
Francois Dalencon
Patricia Probeck-Quellec
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507240A external-priority patent/FR2888117B1/fr
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE424845T1 publication Critical patent/ATE424845T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
AT06778810T 2005-07-07 2006-07-07 Thermoreversible immunadjuvansemulsion ATE424845T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (fr) 2005-07-07 2005-07-07 Composition vaccinale comprenant une emulsion thermoreversible
FR0508310 2005-08-04

Publications (1)

Publication Number Publication Date
ATE424845T1 true ATE424845T1 (de) 2009-03-15

Family

ID=37637538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06778810T ATE424845T1 (de) 2005-07-07 2006-07-07 Thermoreversible immunadjuvansemulsion

Country Status (24)

Country Link
EP (2) EP1904099B1 (de)
JP (1) JP5300475B2 (de)
KR (1) KR101328638B1 (de)
CN (1) CN101217977B (de)
AR (1) AR054822A1 (de)
AT (1) ATE424845T1 (de)
AU (1) AU2006268466B2 (de)
BR (1) BRPI0614053A2 (de)
CA (1) CA2613732C (de)
CY (2) CY1108994T1 (de)
DE (1) DE602006005671D1 (de)
DK (2) DK2080522T3 (de)
EA (1) EA012376B1 (de)
ES (2) ES2390104T3 (de)
IL (1) IL187967A0 (de)
MX (1) MX2007016412A (de)
NO (1) NO336369B1 (de)
NZ (1) NZ564173A (de)
PL (2) PL1904099T3 (de)
PT (2) PT1904099E (de)
SG (1) SG163584A1 (de)
SI (2) SI1904099T1 (de)
TN (1) TNSN08001A1 (de)
WO (1) WO2007006939A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1861120T3 (en) 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2011213757B2 (en) * 2005-11-04 2013-07-25 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
NZ594482A (en) * 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
EP2043682B1 (de) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenzaimpfstoff
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
JP2010530362A (ja) * 2007-05-31 2010-09-09 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 皮内ｈｐｖペプチドワクチン接種
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
CN105944095B (zh) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
WO2010096868A1 (en) * 2009-02-25 2010-09-02 Stiefel Research Australia Pty Ltd Topical foam composition
NZ599666A (en) 2009-10-09 2014-11-28 Cbio Ltd Chaperonin 10 variants
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
AU2011336366B2 (en) 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
WO2012100302A1 (en) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Combination vaccines
EP2578974A1 (de) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Verfahrenslinie zur Herstellung von gefriergetrockneten Partikeln
NZ714625A (en) 2012-03-23 2017-02-24 Pitney Pharmaceuticals Pty Ltd Kinase inhibitors for the treatment of cancer
HK1203358A1 (en) 2012-06-05 2015-10-30 The Australian National University Vaccination with interleukin-4 antagonists
WO2013184900A2 (en) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
KR20150036592A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
EP3202397B1 (de) 2012-08-06 2019-09-25 Pitney Pharmaceuticals Pty Limited Verbindungen zur behandlung von durch den mtor-pfad vermittelten erkrankungen
CN103784953B (zh) * 2012-10-26 2018-04-10 上海医药工业研究院 作为疫苗佐剂的水包油型亚微乳及其制备方法
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
EP2931296B1 (de) 2012-12-17 2019-02-27 NewSouth Innovations Pty Limited Behandlung von krankheiten mit mucin
EP3446708A1 (de) 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Impfstoffe zur behandlung von krebs und zusammensetzungen zur erhöhung der impfstoffwirksamkeit
EP3016968B1 (de) 2013-07-01 2019-06-26 Newsouth Innovations Pty Limited Diagnose und behandlung von autoimmunkrankheiten
CN105288614A (zh) * 2014-06-18 2016-02-03 潘皓 一种疫苗组合物及其制备方法
EP3171954B1 (de) 2014-07-21 2018-06-27 Sanofi Pasteur SA Flüssigkeitszuführvorrichtung zur erzeugung von tröpfchen und deren verwendung zur herstellung eine impfstoffzusammensetzung
CN116603058A (zh) 2015-03-26 2023-08-18 Gpn疫苗有限公司 链球菌疫苗
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
BR112018069100A2 (pt) * 2016-03-23 2019-01-29 Intervet International B.V. uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
US12065482B2 (en) 2016-08-10 2024-08-20 Celltrion Inc. Stable liquid pharmaceutical formulation of anti-influenza virus antibody
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
KR20230054719A (ko) 2020-08-24 2023-04-25 사노피 파스퇴르 인크 Sars-cov-2 감염에 대한 백신
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
CN118662475B (zh) * 2023-03-16 2026-02-06 清华大学 固体化自微乳疫苗的制备与应用
IL324411A (en) 2023-05-05 2026-01-01 Sanofi Pasteur Inc Preparations for use in the treatment of acne
CN116531514A (zh) * 2023-05-29 2023-08-04 大连理工大学 一种烷基糖苷表面活性剂在铝佐剂冻干中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
EP0436537A4 (en) 1988-01-29 1992-04-08 Chiron Corporation Recombinant cmv neutralizing proteins
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US6299848B1 (en) * 1998-09-25 2001-10-09 Hamon Research-Cottrell Process for removing sulfur dioxide out of a gas
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
DE60233934D1 (de) * 2001-03-21 2009-11-19 Madash Llc Thermisch reversible wasser-in-öl-in-wasser-emulsionen
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
PL2080522T3 (pl) 2012-11-30
PL1904099T3 (pl) 2009-08-31
IL187967A0 (en) 2008-03-20
PT2080522E (pt) 2012-10-01
MX2007016412A (es) 2008-03-07
CA2613732A1 (en) 2007-01-18
SI1904099T1 (sl) 2009-08-31
NO336369B1 (no) 2015-08-10
JP2009500382A (ja) 2009-01-08
KR101328638B1 (ko) 2013-11-27
EP2080522A1 (de) 2009-07-22
ES2322102T3 (es) 2009-06-16
EP1904099B1 (de) 2009-03-11
JP5300475B2 (ja) 2013-09-25
ES2390104T3 (es) 2012-11-06
CY1113414T1 (el) 2016-06-22
DK2080522T3 (da) 2012-10-08
DE602006005671D1 (en) 2009-04-23
CN101217977B (zh) 2013-03-06
AU2006268466A1 (en) 2007-01-18
CY1108994T1 (el) 2014-07-02
WO2007006939A2 (fr) 2007-01-18
NZ564173A (en) 2010-10-29
CN101217977A (zh) 2008-07-09
EP2080522B1 (de) 2012-07-04
NO20080585L (no) 2008-03-26
BRPI0614053A2 (pt) 2011-03-09
AU2006268466B2 (en) 2011-11-10
TNSN08001A1 (fr) 2009-07-14
CA2613732C (en) 2013-12-10
DK1904099T3 (da) 2009-06-08
EP1904099A2 (de) 2008-04-02
SI2080522T1 (sl) 2012-10-30
AR054822A1 (es) 2007-07-18
EA200800271A1 (ru) 2008-04-28
EA012376B1 (ru) 2009-10-30
KR20080030076A (ko) 2008-04-03
SG163584A1 (en) 2010-08-30
WO2007006939A3 (fr) 2007-04-05
PT1904099E (pt) 2009-05-29

Similar Documents

Publication Publication Date Title
DK2080522T3 (da) Termoreversibel immunoadjuvansemulsion
DE502005003444D1 (de) Drohne
DE602005024549D1 (de) Reifenverschleisssystem
DE502005010582D1 (de) Kabeldurchführung
DE602005021995D1 (de) Tintenstrahldrucker
DE112005001624A5 (de) Brillengestell
DE602005026472D1 (de) Tintenstrahldrucker
DE602005006955D1 (de) Klopferkennung
FR2882056B1 (fr) Dipyrromethenes-bore borocarbones insatures
EP1705025A4 (de) Drucker
DE602005019976D1 (de) Siebdrucker
DE602005012725D1 (de) Htvermögens
DK1848727T3 (da) Ibandronat polymorf b
DE602006000877D1 (de) Emulsionszusammensetzung
DE502005007739D1 (de) Kranballastierungssystem
DE502005008587D1 (de) Kugelgelenk
DE602005002296D1 (de) Buschschneider
DE602006021373D1 (de) Zündgerät
DE602005007826D1 (de) Tintenstrahldrucker
DE602005003649D1 (de) Hydraulikhammer
EP1719628A4 (de) Drucker
DE602005009310D1 (de) Tintenstrahldrucker
EP1942006A4 (de) Drucker
DE602006011850D1 (de) Thermotransfer - empfangsblatt
DE502005007584D1 (de) Raftfahrzeuge

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1904099

Country of ref document: EP